Logo image of SLS

SELLAS LIFE SCIENCES GROUP I (SLS) Stock Fundamental Analysis

NASDAQ:SLS - Nasdaq - US81642T2096 - Common Stock - Currency: USD

1.7465  -0.19 (-9.97%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SLS. SLS was compared to 561 industry peers in the Biotechnology industry. The financial health of SLS is average, but there are quite some concerns on its profitability. SLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SLS had negative earnings in the past year.
SLS had a negative operating cash flow in the past year.
SLS had negative earnings in each of the past 5 years.
In the past 5 years SLS always reported negative operating cash flow.
SLS Yearly Net Income VS EBIT VS OCF VS FCFSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -227.81%, SLS is doing worse than 91.80% of the companies in the same industry.
SLS's Return On Equity of -1182.35% is on the low side compared to the rest of the industry. SLS is outperformed by 83.78% of its industry peers.
Industry RankSector Rank
ROA -227.81%
ROE -1182.35%
ROIC N/A
ROA(3y)-292.14%
ROA(5y)-216.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLS Yearly ROA, ROE, ROICSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLS Yearly Profit, Operating, Gross MarginsSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

SLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SLS has more shares outstanding than it did 1 year ago.
SLS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLS Yearly Shares OutstandingSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SLS Yearly Total Debt VS Total AssetsSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -20.25, we must say that SLS is in the distress zone and has some risk of bankruptcy.
SLS's Altman-Z score of -20.25 is on the low side compared to the rest of the industry. SLS is outperformed by 86.99% of its industry peers.
SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.25
ROIC/WACCN/A
WACC9.9%
SLS Yearly LT Debt VS Equity VS FCFSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 1.02 indicates that SLS should not have too much problems paying its short term obligations.
SLS has a worse Current ratio (1.02) than 89.30% of its industry peers.
A Quick Ratio of 1.02 indicates that SLS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.02, SLS is not doing good in the industry: 87.88% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
SLS Yearly Current Assets VS Current LiabilitesSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.45% over the past year.
EPS 1Y (TTM)65.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 42.54% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.16%
EPS Next 2Y9.27%
EPS Next 3Y24.13%
EPS Next 5Y42.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLS Yearly Revenue VS EstimatesSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2020 2021 2022 2023 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
SLS Yearly EPS VS EstimatesSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2K -4K -6K -8K -10K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLS Price Earnings VS Forward Price EarningsSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLS Per share dataSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as SLS's earnings are expected to grow with 24.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.27%
EPS Next 3Y24.13%

More info and screens

0

5. Dividend

5.1 Amount

SLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (5/21/2025, 3:12:05 PM)

1.7465

-0.19 (-9.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners9.36%
Inst Owner Change110.33%
Ins Owners1.14%
Ins Owner Change52.24%
Market Cap165.13M
Analysts82.86
Price Target5.95 (240.68%)
Short Float %8.18%
Short Ratio5.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.98%
Min EPS beat(2)-29.95%
Max EPS beat(2)21.99%
EPS beat(4)1
Avg EPS beat(4)-2524.49%
Min EPS beat(4)-8900.9%
Max EPS beat(4)21.99%
EPS beat(8)3
Avg EPS beat(8)-1270.51%
EPS beat(12)3
Avg EPS beat(12)-864.45%
EPS beat(16)5
Avg EPS beat(16)-648.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 56.69
P/tB 165.3
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.03
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -227.81%
ROE -1182.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-292.14%
ROA(5y)-216.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z -20.25
F-Score3
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y27.16%
EPS Next 2Y9.27%
EPS Next 3Y24.13%
EPS Next 5Y42.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.37%
OCF growth 3YN/A
OCF growth 5YN/A